2. Academic Validation
  3. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

  • Front Immunol. 2024 Apr 15:15:1331217. doi: 10.3389/fimmu.2024.1331217.
James G Krueger 1,  Kilian Eyerich 2 3,  Vijay K Kuchroo 4,  Christopher T Ritchlin 5,  Maria T Abreu 6,  M Merle Elloso 7,  Anne Fourie 8,  Steven Fakharzadeh 9,  Jonathan P Sherlock 10 11,  Ya-Wen Yang 9,  Daniel J Cua 10,  Iain B McInnes 12
Affiliations

Affiliations

  • 1 Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, United States.
  • 2 Department of Medicine, Division of Dermatology and Venereology, Karolinska Institute, Stockholm, Sweden.
  • 3 Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg, Germany.
  • 4 Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
  • 5 Allergy, Immunology & Rheumatology Division, Center for Musculoskeletal Research, University of Rochester Medical School, Rochester, NY, United States.
  • 6 Division of Gastroenterology, Department of Medicine, University of Miami Leonard Miller School of Medicine, Miami, FL, United States.
  • 7 Janssen Scientific Affairs, LLC, Horsham, PA, United States.
  • 8 Janssen Research & Development, LLC, San Diego, CA, United States.
  • 9 Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, United States.
  • 10 Janssen Research & Development, LLC, Spring House, PA, United States.
  • 11 Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
  • 12 College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
PMID: 38686385 DOI: 10.3389/fimmu.2024.1331217
Abstract

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti-IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23-driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.

Keywords

IL-23; cytokine; immune-mediated inflammatory diseases; inflammatory bowel disease; psoriasis; psoriatic arthritis.

Figures